Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens

QIUBO YU1, YANAN LI1, GANG LI1, TINGHONG LI1, HAN ZENG1, ZHU YANG1 and DELING WANG2

1Cell Genetics Laboratory, Molecular Medical Laboratory Center; 2Department of Urological Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China

Received March 16, 2015; Accepted March 22, 2016

DOI: 10.3892/ol.2016.4592

Abstract. The aim of the present study was to estimate the diagnostic value of fluorescence in situ hybridization (FISH) analysis of tumor cells in voided urine specimens for detecting upper tract urothelial carcinoma (UTUC). Cytology and FISH analyses were conducted on voided urine collected in the morning from 125 patients with suspected UTUC. During follow-up, ureteroscopy with biopsy and histopathology were used to confirm the presence of tumors. The average follow-up time was 23.8 months (range, 6-36 months). A total of 8 patients who could not be contacted until the last follow-up were excluded from the study. Of the remaining 117 patients, 19 were histologically demonstrated to have UTUC, of whom, 3 patients had stage pTis disease, 6 had stage pTa disease, 5 had stage pT1 disease and 5 had stage pT2 disease (7 G1, 8 G2 and 4 G3). The overall sensitivity of FISH to detect UTUCs in voided urine specimens was 84.21% (16/19), whereas that of cytology was 42.11% (8/19) (P<0.05). The overall specificity of FISH to detect UTUCs in voided urine specimens was 89.80% (88/98), compared with 94.90% (93/98) of cytology (P>0.05). The positive predictive value (PPV) and negative predictive value of FISH were 80.00% (16/20) and 97.78% (88/90), respectively, whereas those of cytology were 100.00% (8/8) (P>0.05) and 90.29% (93/103) (P>0.05), respectively. The present data indicated that FISH was a method capable of detecting UTUCs in voided urine specimens with good sensitivity and specificity, although it exhibited a high rate of false positivity and low PPV.

Introduction

Cancerous lesions of the renal pelvis and ureter are malignant tumors that arise from the urothelial (transitional cell epithelium) mucosa of the renal pelvis or ureter (1). Primary urinary tract urothelial carcinomas (UTUCs) are rare tumors with an estimated incidence of 1-4 cases/100,000 individuals/year (1). UTUC is much less common than bladder cancer, and only accounts for ~5% of all urothelial carcinoma cases (2). A total of 90% of UTUCs are transitional cell carcinomas (2). Ureteral tumors are particularly rare (1,3), and their incidence rate is ~1/4 that of renal pelvic tumors (1).

The majority of patients with UTUC present with flank pain or hematuria at the early stages of the disease (4). Suspected UTUCs are usually evaluated with intravenous pyelography, retrograde pyelography (RGP), ultrasonography (UG), computed tomography (CT), upper tract urinary cytology and cystourethroscopy with biopsy (2,4). Imaging studies usually reveal a filling defect or an obstructive mass, which is often associated with hydronephrosis, hydroureter or renal stones (2). Therefore, despite being non-invasive methods, imaging studies should not be used as the sole diagnostic tool for UTUC, due to their low sensitivity for the detection of small tumors, since numerous causes exist to explain a filling defect other than UTUC (4,5). Cytology has a low sensitivity for detecting UTUC, and ureteroscopy is an invasive method with poor sensitivity, particularly in flat tumors (4,6). The epithelium that covers the renal pelvis, bladder and ureter is mainly transitional. Various tumors may appear in the kidney area, particularly in the renal medulla portion of the kidney, and often require to be identified as potential transitional cell carcinoma of the renal pelvis (4). In addition, renal pelvic cancer and blood clots in the renal pelvis are often difficult to identify by imaging techniques (5).

Due to the above mentioned shortcomings, the identification of sensitive molecular markers for the detection of UTUC is urgently required. To date, only a limited number of sensitively accepted markers have been applied to detect urinary tumors, including ImmunnoCyt™/uCyt™ and fluorescence in situ hybridization (FISH) technology (7-9). FISH technology is generally used for the diagnosis of bladder cancer in voided urine in China, due to its high sensitivity and specificity, but its use for detecting UTUCs is limited, due to its low reliability (10). Luo et al (10) reviewed the utility of
FISH in the diagnosis of UTUC, but this type of prospective study has not been conducted in China thus far. Thus, in the present study, the sensitivity and specificity of FISH technology for detecting suspicious UTUCs in voided urine specimens was prospectively estimated, since this type of specimens are easily collected and accepted by patients.

Materials and methods

Patients and samples. Between May 2011 and August 2014, voided urine from 125 patients (82 males and 43 females; mean age, 61.4 years; range, 45-92 years) with suspicion of UTUC were analyzed prospectively. Patients were recruited from The First, The Second and The Fifth Affiliated Hospitals of Chongqing Medical University (Chongqing, China). Patients with clinical symptoms (gross hematuria, flank pain) and/or radiographic (UG or CT) abnormalities suggestive of UTUC, localising hematuria, such as blood efflux from the ureteral orifice, and atypical obstruction were included in the study. The patients were followed up for a mean ± standard deviation observation time of 23.8±7.5 months (range, 5-39 months). First-time voided urine specimens, which were the first morning urine specimens at the time of admission to hospital, were collected for FISH and cytology tests in the morning. Urinary cells from voided urine were sedimented at 600 g for 10 min in a Sorvall Legend Mach 1.6R benchtop centrifuge (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and the cell pellets were divided into two equal volumes, one of which was used for FISH and one for cytology analyses. The ethics committee of Chongqing Medical University (Chongqing, China) approved the present study, and all patients provided their informed consent prior to participation.

Cytology. Urinary cytology was performed according to the Papanicolaou method (11), using an eosin alcohol 50 solution (Hubei Taikang Medical Equipment Co., Ltd., Hubei, China). Cytology was scored as positive, negative or suspicious by a senior cytologist. Suspicious cytology was defined as those samples that contained cells with morphologies that could not be clearly classified as tumor or normal cells. Histopathological classification was performed according to the Union for International Cancer Control criteria (8,9).

FISH. Cell pellets were resuspended in 10 ml preheated hypotonic solution [0.075 mol/l potassium chloride (Hubei Taikang Medical Equipment Co., Ltd.),] and incubated at 37°C for 25 min, pipetting three times during this period of time to ensure a sufficient hypotonic environment for the cells. Next, cells were sedimented at 600 g for 10 min, and the cell pellets were fixed in 3:1 (v/v) methanol:glacial acetic acid (Hubei Taikang Medical Equipment Co., Ltd.). The final cell pellet was resuspended in the appropriate volume of fixing liquid, according to the number of urinary cells. One or two drops of the resuspended cells (10⁷-10⁹ cells/ml) were seeded onto two glass slides (Hubei Taikang Medical Equipment Co., Ltd.) and incubated at 60°C for 2 h.

The glass slides were then incubated at 37°C with RNase A solution [40 ml 2X saline-sodium citrate (SSC) solution with 60 µl 100 g/ml RNase A; Beijing GP Medical Technologies, Ltd. (Beijing, China)] for 30 min, followed by incubation with pepsin solution [40 ml 0.01 M HCl (Hubei Taikang Medical Equipment Co., Ltd.) with 160 µl 20 mg/ml pepsin (Beijing GP Medical Technologies, Ltd.)] at 37°C for 10 min. The slides were then washed twice in 2X SSC solution for 5 min each, and sequentially dehydrated in 70, 85 and 100% ethanol (3 min each) (Hubei Taikang Medical Equipment Co., Ltd.). The slides were then denatured in 70% formamide (Hubei Taikang Medical Equipment Co., Ltd.)/2X SSC denaturing solution at 73°C for 5 min, and gradient-dehydrated in 70, 85 and 100% ethanol.

The probe mix used for FISH analysis consisted of centromere enumeration probes (CEPs) of chromosomes 3, 7 and 17, and locus-specific identifier probes to the locus 9p21 of the tumor suppressor gene p16 (Hubei Taikang Medical Equipment Co., Ltd., Beijing, China). Under dry and dark conditions, the probe mixture [8 µl hybridization buffer solution (Hubei Taikang Medical Equipment Co., Ltd.) and 2 µl probe] was prepared, and next denatured at 73°C for 5 min in an electric-heated thermostat water bath (HH.S11-Ni2; Hubei Taikang Medical Equipment Co., Ltd.). The probe mixture was then added to the slides and incubated overnight (>17 h) at 42°C for hybridization. In order to prevent volatilization of the probe mixture, seal slips were used to cover the hybridized area, and sealing film was mounted in the surrounding gap.

The following day, the slides were dehydrated in 70% ethanol, and naturally dried prior to be stained with 4',6-diamidino-2-phenylindole (DAPI). Cells with three-color fluorescent hybridization signals (DAPI/fluorescein isothiocyanate/tetramethylrhodamine; fluorescence in situ hybridization detection kit; GP Medical Technologies, Ltd.) were observed under a microscope (BX51; Olympus Corporation, Tokyo, Japan). Image analysis was performed with VideoTesT-FISH 2.0 software (Digital Imaging Systems Ltd., Bourne End, UK).

All cases were screened by a cytotechnologist with specific training in FISH interpretation. Specimens were considered to be abnormal when presenting >12 cells with heterozygosity loss or homozygosis loss of solely p16, or >4 aneusomic cells of >2 other probes. Positive cases were confirmed by a second cytotechnologist. In addition, specimens were also considered to be abnormal if contained 25 cells with tetrasomy, which corresponded to 4 signals in each of the 4 probes analyzed.

Statistical analysis. Statistical analysis for evaluating the differences between cytology and FISH was performed using two-sided Fisher's exact test. When not applicable, χ² test was performed instead (7). P<0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA).

Results

A total of 125 voided urine specimens from 125 patients were collected in the present study. The average follow-up time following cytology and FISH assay was 23.8 months (range, 5-39 months). Of the 125 patients, 8 could not be contacted until the last follow-up, and were therefore excluded from the study. The voided urine specimens from the remaining 117 patients were analyzed in the present study, 79 of whom were men and 38 women. Cytology could not be performed in 6 of the 117 samples due to insufficient number of cells in
The average follow-up time was 21.42 months (range, 6-36 months). One patient experienced recurrence of bladder cancer in the left ureter after 33 months of bladder cancer excision.

Fig. 1 reveals abnormal and normal FISH signals of CEP3, CEP7, CEP17 and gene locus-specific p16. Fig. 1A and B represent tumor cells, while Fig. IC and D represent normal cells.

**Discussion**

UTUC is not a frequent type of urological cancer, accounting for only 5% of all transitional cell carcinomas of the urinary system (12). UTUCs tend to present high grade and stage, and are usually associated with poor prognosis (12). Therefore, early diagnosis and effective treatment for UTUC is imperative (4,13). ImmunoCyt/uCyt+ test, voided or clean catch urine cytology, radiographic or ultrasound imaging and ureteroscopy are the most common diagnostic methods for UTUC (7). However, urine cytology has been reported to be of little value in evaluating unclear or suspicious findings of the upper urinary tract obtained by imaging studies (14,15), which have a sensitivity of 30-50% (16,17). Furthermore, radiographic and ultrasound imaging have low sensitivity for the detection of carcinoma in situ in small lesions, and ureteroscopy is an invasive method which patients prefer to avoid (4).

FISH was previously reported to have a high sensitivity and specificity for detecting bladder cancer (18). Few retrospective studies on FISH demonstrated that FISH had high sensitivity and specificity in detecting UTUC, contrarily to cytology (4,7,10). However, the majority of those studies were

---

### Table I. Cytology data compared with histology data (n=117).

| Cytology       | Histology  | Total |
|----------------|------------|-------|
|                | Urothelial lesions | Negative |     |
| Positive       | 8          | 0     | 8    |
| Negative       | 10         | 93    | 103  |
| Nondiagnostic  | 1          | 5     | 6    |
| Total          | 19         | 98    | 117  |

### Table II. FISH data compared with histology data (n=117).

| FISH            | Histology  | Total |
|-----------------|------------|-------|
|                 | Urothelial lesions | Negative |     |
| Positive        | 16         | 4     | 20   |
| Negative        | 2          | 88    | 90   |
| Nondiagnostic   | 1          | 6     | 7    |
| Total           | 19         | 98    | 117  |

### Table III. Sensitivity, specificity and predictive value of FISH data compared with cytology data.

| Histology, % (n=117) | Cytology, % | FISH, % | P-value |
|----------------------|-------------|---------|---------|
| Sensitivity          | 42.11 (8/19)| 84.21 (16/19) | 0.01* |
| Specificity          | 94.90 (93/98)| 89.80 (88/98) | 0.09 |
| False positive       | 0.00 (0/8)  | 20.00 (4/20)  | 0.24 |
| False negative       | 9.71 (10/103)| 2.20 (2/90)   | 0.02* |
| PPV                  | 100.00 (8/8) | 80.00 (16/20) | 0.24 |
| NPV                  | 90.29 (93/103)| 77.78 (88/90) | 0.02* |

*Statistically significant difference (P<0.05). FISH, fluorescence in situ hybridization; PPV, positive predictive value; NPV, negative predictive value.

---

these urine samples, while the fluorescence signals of FISH test in 7 specimens could not be interpreted. As an insufficient number of cells in urine is typically voided during FISH, all these patients, which were regarded as non-diagnostic, were included in the subsequent statistical analysis in order to estimate the overall sensitivity and specificity of FISH. Of the 117 patients, 19 had histologically confirmed UTUC, of whom, 6 exhibited stage pTa disease, 5 stage pT1 disease, 5 stage pT2 disease and 3 stage pTis disease (7 G1, 8 G2 and 4 G3).

Tables I and II indicate the characteristics of the study population. Table I contains the cytology data of 117 patients, while their FISH data is presented in Table II. Table III reveals the sensitivity, specificity and predictive value of FISH and cytology tests.
Table IV. Histopathological classification and other findings of 19 upper tract urothelial carcinomas.

| No. | Gender | Age (years) | H | Bladder cancer recurrence | Location of lesion | Follow-up time (months) | TCC stage/grade | Cytology | FISH |
|-----|--------|-------------|---|---------------------------|-------------------|-------------------------|----------------|----------|------|
| 1   | Male   | 54          | MH| Yes                       | LU                | 33                      | pT2/G2         | Positive | Positive |
| 2   | Male   | 68          | None| No                        | RRP               | 28                      | pTa/G1         | Negative | Positive |
| 3   | Male   | 72          | None| No                        | LU                | 36                      | pT2/G3         | Positive | Positive |
| 4   | Female| 71          | None| No                        | LRP               | 35                      | pT1/G2         | Negative | Positive |
| 5   | Male   | 65          | MH | No                        | LRP               | 29                      | pTis/G1        | Positive | Negative |
| 6   | Male   | 82          | None| No                        | RRP               | 26                      | pT1/G2         | Negative | Positive |
| 7   | Male   | 48          | GH | No                        | RRP               | 31                      | pTis/G1        | Positive | Positive |
| 8   | Female| 63          | None| No                        | LRP               | 22                      | pTa/G2         | Negative | Positive |
| 9   | Male   | 77          | GH | No                        | LRP               | 24                      | pT2/G3         | Positive | Positive |
| 10  | Male   | 65          | None| No                        | RU                | 19                      | pT1/G1         | Positive | Negative |
| 11  | Male   | 51          | MH | No                        | RU                | 24                      | pTa/G1         | Negative | Positive |
| 12  | Female| 53          | None| No                        | LRP               | 12                      | pT1/G2         | Negative | Positive |
| 13  | Male   | 73          | None| No                        | RU                | 9                       | pTa/G2         | Negative | Positive |
| 14  | Female| 61          | None| No                        | LRP               | 8                       | pTis/G1        | Negative | Positive |
| 15  | Male   | 56          | MH | No                        | RU                | 16                      | pTis/G2        | Nondiagnostic | Nondiagnostic |
| 16  | Male   | 76          | None| No                        | LRP               | 23                      | pT2/G3         | Negative | Positive |
| 17  | Male   | 49          | GH | No                        | RRP               | 17                      | pTa/G1         | Negative | Positive |
| 18  | Male   | 68          | None| No                        | LRP               | 9                       | pT1/G3         | Negative | Positive |
| 19  | Male   | 64          | MH | No                        | RRP               | 6                       | pT2/G2         | Positive | Positive |

H, hematuria; TCC, transitional cell carcinoma; FISH, fluorescence in situ hybridization; GH, gross hematuria; MH, microhematuria; LU, left ureter; RU, right ureter; LRP, left renal pelvis; RRP, right renal pelvis.

Figure 1. Representative images of abnormal and normal FISH signals of CEP3, CEP7, CEP17 and GLP p16. (A) Abnormal FISH signals of CEP3 (red, 6 dots) and CEP7 (green, 7 dots). (B) Abnormal FISH signals of GLP p16 (red, 1 dot) and CEP17 (green, 4 dots). (C) Normal FISH signals of CEP3 (red, 2 dots) and CEP7 (green, 2 dots). (D) Normal FISH signals of GLP p16 (red, 2 dots) and CEP17 (green, 2 dots). Magnification, x1,000. FISH, fluorescence in situ hybridization; CEP, centromere enumeration probe; GLP, gene locus-specific.
hybridisation in the diagnosis of upper urinary tract cancer (9). Thus, the in voided urine and . Therefore, the present authors recommend low-grade tumor specimens. One specimen was false positives detected as a consequence of as a result of patients with UUT in the present study still rendered high sensitivity in detecting cells in their samples, whereas the cut-off value of 4% used in the present study was lower, based on the characteristics of the Chinese study by Reynolds reported by Reynolds to that reported by Gruschwitz detection of UTUC identified in the present study was similar of false-positives and PPV, FISH was similar to cytology. In the present study, the sensitivity of FISH for detecting UTUC was detected in voided urine by FISH within a prospective randomized trial. If the number of cells following centrifugation was not sufficient for visual analysis with the naked eye, all the resuspended cells would be seeded onto glass slides, and the number of aneusomic cells in the whole slide would be counted, in order to increase FISH sensitivity. Combining microscopic observation with analysis of selected images enabled to exclude non-specific signals, thus improving FISH specificity. If numerous hemameba were present, samples would be observed using the DAPI channel with differential cell nucleus refractivity between epithelial cells and hemameba, in order to decrease the interference of hemameba. In the present study, the sensitivity of FISH for detecting UTUC was higher than that of cytology (P=0.01), and the rate of false-negatives of FISH was lower than that of cytology (P=0.02). In addition, the NPV of FISH was superior to that of cytology (P=0.02). However, in terms of specificity, rate of false-positives and PPV, FISH was similar to cytology. Contrarily to a previous study by Huang et al (17), who reported a sensitivity of 100% for FISH in detecting UTUC, the sensitivity identified in the present study was low. This difference may be due to the fact that the majority of patients in the cohort analyzed by Huang et al (17) exhibited high-grade UTUCs, for which the FISH assay has higher sensitivity than for low-grade tumors (17,20). The sensitivity of FISH for the detection of UTUC identified in the present study was similar to that reported by Gruschwitz et al (21), but higher than that reported by Reynolds et al (9). There is a possible reason for this difference. In the study by Reynolds et al (9), specimens were considered to be abnormal by FISH if 10 cells with near-tetrasomy or tetrasomy, or 5 cells with hypertetrasomy were detected. However, the cut-off value used in the present study was lower, based on the characteristics of the Chinese healthy donors who provided voided urine as a control. In the study by Reynolds et al (9), the samples consisted of ureteral washings and renal pelvis brushings, while voided urine specimens were used instead in the present study. Thus, the proportion of upper ureteral epitheliums as contaminated by bladder transitional epitheliums is low in the present study, compared with the study by Reynolds et al (9). Thus, the authors recommend in their study to apply a high cut-off value of 20%, due to the enrichment in upper tract urothelial cells in their samples, whereas the cut-off value of 4% used in the present study still rendered high sensitivity in detecting patients with UUT-UCCs, due to the reduced number of false positives detected as a consequence of as a result of contamination by bladder transitional epitheliums in voided urine specimens. Therefore, the present authors recommend 4% as the cut-off value, which led to 84.21% sensitivity, 89.80% specificity, 2.20% rate of false-negatives and 97.78% NPV for the detection of UTUCs in voided urine by FISH. However, this low cut-off value increased the false-positivity (20.00%) and decreased the PPV (80.00%) of FISH. In the present study, 2 false-negative results of FISH that were positive by cytology corresponded to low-grade tumor specimens, and 7 out of 10 false-negative results of cytology that were positive by FISH were high-grade tumor specimens. One specimen was nondiagnostic by FISH and cytology, due to an insufficient number of cells, but urethroscopy with biopsy during the follow-up demonstrated that it was a pTa G1 tumor in the right ureter.

In summary, the present data demonstrated that it is possible to apply FISH as a method to detect UTUC in voided urine specimens. FISH displayed good sensitivity and specificity when the cut-off value was 4%, but this increased its rate of false-positivity and decreased its PPV. In the present study, FISH was observed to be a clinical reliable method for the detection of UTUC, with a higher sensitivity than cytology and equal specificity. In order to improve FISH specificity, non-specific signals were excluded between microscopic observation and analysis upon image selection. With regard to positive FISH results, further examination or follow-up are strongly recommended.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (Beijing, China; grant no. 81100443), Chongqing Yuzhong District Science and Technology Plan (project no. 20120214) and Chongqing Municipal Health Bureau (scientific research project no. 2013-2-151).

References

1. Oya M and Kikuchi E; Committee for Establishment of Clinical Practice Guideline for Management of Upper Tract Urothelial Carcinoma; Japanese Urological Association: Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary - Japanese Urological Association, 2014 edition). Int J Urol 22: 3-13, 2015.
2. Gupta R, Paner GP and Amin MB: Neoplasms of the upper urinary tract: A review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol 15: 127-139, 2008.
3. Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J and Rouprêt M: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104: 1436-1440, 2009.
4. Marin-Aguilera M, Mengual L, Ribal MJ, Musquera M,Ars E, Villaviciencio H, Algabe F and Alcaraz A: Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 51: 409-415, 2007.
5. Mills IW, Laniado ME and Patel A: The role of endoscopy in the management of patients with upper urinary tract transitional cell carcinoma. BJU Int 87: 150-162, 2001.
6. Wiener HG, Mian C, Haitel A, Pyccha A, Schatzl G and Marberger M: Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 159: 1876-1880, 1998.
7. Mian C, Mazzoleni G, Vikoler S, Martini T, Knüchel-R Clark R, Haitel A, Berthon N, Villers A, Biserte J, Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J and Rouprêt M: Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104: 1436-1440, 2009.
8. Marin-Aguilera M, Mengual L, Ribal MJ, Musquera M,ars E, Villaviciencio H, Algabe F and Alcaraz A: Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 51: 409-415, 2007.
9. Mills IW, Laniado ME and Patel A: The role of endoscopy in the management of patients with upper urinary tract transitional cell carcinoma. BJU Int 87: 150-162, 2001.
8. Sobin LH and Wittekind CH (eds): Urological tumours: Bladder. In: TNM Classification of Malignant Tumours. 6th edition. John Wiley & Sons, Hoboken, NJ, pp199-202, 2002.

9. Reynolds JP, Voss JS, Kipp BR, Karnes RJ, Nassar A, Clayton AC, Henry MR, Sebo TJ, Zhang J and Halling KC: Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol 122: 459-467, 2014.

10. Luo B, Li W, Deng CH, Zheng FF, Sun XZ, Wang DH and Dai YP: Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet 189: 93-97, 2009.

11. May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M and Hoschke B: Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 70: 449-453, 2007.

12. Oosterlinck W, Solona E, van der Meijden AP, Sylvester R, Böhle A, Rintala E and Lobel B; European Association of Urology: EAU guidelines on diagnosis and treatment of upper tract transitional cell carcinoma. Eur Urol 46: 147-154, 2004.

13. Stewart GD, Bariol SV, Grigor KM, Tolley DA and McNeill SA: A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 95: 791-793, 2005.

14. Akkad T, Brunner A, Pallwein L, Gozzi C, Bartisch G, Mikuz G, Steiner H and Verdorfer I: Fluorescence in situ hybridization for detecting upper urinary tract tumors - a preliminary report. Urology 70: 753-757, 2007.

15. Zincke H, Aguilo JJ, Farrow GM, Utz DC and Khan AU: Significance of urinary cytology in the early detection of transitional cell cancer of the upper urinary tract. J Urol 116: 781-783, 1976.

16. Lodde M, Mian C, Wiener H, Haitel A, Pycha A and Marberger M: Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: A preliminary report. Urology 58: 362-366, 2001.

17. Huang WT, Li LY, Pang J, Ruan XX, SunQP, Yang WJ and Gao X: Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology. Neoplasma 59: 355-360, 2012.

18. Song M-J, Lee H-M and Kim S-H: Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer. Cancer Genet Cytogenet 198: 144-150, 2010.

19. Shan Z, Wu P, Zheng S, Tan W, Zhou H, Zuo Y, Qi H, Zhang P, Peng H and Wang Y: Evaluation of upper urinary tract tumors by FISH in Chinese patients. Cancer Genet Cytogenet 203: 238-246, 2010.

20. Chen AA and Grasso M: Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol 22: 1371-1374, 2008.

21. Gruschwitz T, Gajda M, Enkelmann A, Grimm MO, Wunderlich H, Horstmann M and Junker K: FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. Int Urol Nephrol 46: 1769-1774, 2014.